Источники. 1. MaLAM, letter to Roussel, Mar 1991; Anon., MaLAM questions Roussel on arginine aspartate

1. MaLAM, letter to Roussel, Mar 1991; Anon., "MaLAM questions Roussel on arginine aspartate", Scrip, No 1609, 19 Apr 1991, p13.

2. Clayton, P., "Can a pill make you more intelligent?", Evening Standard (London), 24 Jul 1991.

3. ВВС, Food for Thought (Transcript of "Horizon" programme transmitted 10 Jun 1991), London, Broadcasting Support Services, 1991, p21.

4. Moran,J., Alzheimer's Disease: New Therapies and the World Market, London, Financial Times Management Reports, 1991.

5. Melville, A. and Johnson, C., Cured to Death, London, New English Library, 1982, pp72-4.

6. Braithwaite, J., Corporate Crime in the Pharmaceutical Industry, London, Routledge & Kegan Paul, 1984, p222.

7. Melville and Johnson, op cit, pp72-4.

8. AMA, Drug Evaluations, Philadelphia, W.B, Saunders Co., (6th edn) 1986, p162.

9. Brown, C.S., "Treatment of attention deficit hyperactivity disorder: a critical review", DICP, The Annals of Pharmacotherapy, Vol 25, Nov 1991, pp1207-13.

10. AMA, op cit, p163.

11. Hechtman, L., "Resilience and vulnerability in long term outcome of attention deficit hyperactive disorder", Canadian Journal of Psychiatry, Vol 36, No 6, Aug 1991, pp415-21.

12. Everett, J., Thomas, J., et al, "Cognitive effects of psychostimulant medication in hyperactive children", Child Psychiatry and Human Development, Vol 22, No 2, Winter 1991, pp79-87.

13. Rosenberger, P.B., "Attention deficit", Pediatric Neurology, Vol 7, No 6, 1991, pp397-405.

14. Rylance, G. (ed.), Drugs for children, Copenhagen, WHO, 1987, p89.

15. E. Merck, Encephabol Prospectus, Darmstadt (Germany), Jan 1986 (English translation of the German original for the company by J.T. Lazarides).

16. Rylance, op cit, p89.

17. MaLAM, letter to E. Merck, Apr 1988.

18. Hosking, G., "Drug marketing in the Third World", Lancet, 1986 (Vol II), p164.

19. Silverman, M., Lydecker, M. and Lee, P.R., Bad Medicine: the prescription drug industry in the Third World, Stanford, Stanford University Press, 1992, pp35-6, 298-9.

20. Parish, P., Medicines: a guide for everybody, London, Penguin (6th edn, revised), 1989, p174.

21. Gilman, A.G., Rail, T.W., Nies, A.S., and Taylor, P., Goodman and Gilman's The Pharmacological Basis of Therapeutics, New York, Pergamon Press, (8th edn) 1990, p781.

22. BMA and the Royal Pharmaceutical Society of Great Britain, British National Formulary, London, BMA and The Pharmaceutical Press, No 23, Mar 1992, p92.

23. Birley, J.L.T., "Drug advertising in developing countries", Lancet, 28 Jan 1989, p220.

24. Mansfield, P.R., "Classifying improvements to drug marketing and justifications for claims of efficacy", International Journal of Risk & Safety in Medicine, Vol 2,1991, pp171-84.

25. Silverman, et al, pp33-6 and 289-99.

26. MaLAM Newsletter, Aug 1987.

27. Anon., "Germans restrict flunarizine use", Scrip, No 1599, 15 Mar 1991, p23.

28. Anon., "CPMP restricts flunarizine indications", Scrip, No 1601, 22 Mar 1991, p22.

29. AMA, op cit, p162.

30. Anon., "Monitor: R&D And Expansion To Boost Sandoz", IMS Marketletter, 14 Nov 1988 (according to Mark Edmiston and Kah Foo of SBCI Savory Milln).

31. Gilman, et al, p946.

32. BMA and the Royal Pharmaceutical Society of Great Britain, op cit, p92.

33. Reynolds, J.E.F. (ed.), Martindale: The Extra Pharmacopoeia, London, The Pharmaceutical Press, (29th edn) 1989, p1051.

34. Physicians' Desk Reference, Oradell, NJ, Medical Economics Company, 44th edn, 1990, p1939.

35. Thompson, T.L., Filley, C.M., et al, "Lack of efficacy of Hydergine in patients with Alzheimer's disease", New England Journal of Medicine, Vol 323, No 7, 16 Aug 1990, pp445-8.

36. Anon., "Ergoloid mesylates ban urged in US", Scrip, No 1592, 20 Feb 1991, p23.

37. Anon., "Present drugs fail in claudication", Scrip, No 1487, 9 Feb 1990, p27.

38. Anon., "Top 50 branded products worldwide", Scrip, Review issue 1990, p21 (based on Barclay de Zoete Wedd's "Pharmaceutical Industry Perspectives").

39. Anon., "Hoechst's 1989 pharma sales up 13.6%", Scrip, No 1516, 23 May 1990, p11.

40. Anon., "Swedes reject pentoxifylline", Scrip, No 1601, 22 Mar 1991, p21.

41. Cookson, С., "New era looks to mind drugs", Financial Times, 26 Jun 1992, p12.

42. Anon., "Economic prescribing", Drug and Therapeutics Bulletin, Vol 29, No 2, 21 Jan 1991, p5.

43. Anon., "Alzheimer's: the path of forgotten memories", Health Horizons, No 13, May 1991, pp26-8.

44. Anon., "FDA panel urges further efficacy studies for Cognex", Scrip, No 1636, 24 Jul 1991, pp24-5.

45. Anon., "Tacrine's benefits confirmed", Scrip, No 1770, 13 Nov 1992, p29.

46. Anon., "Mentane risk-benefit unacceptable", Scrip, No 1769, 10 Nov 1992, pp22-3.

47. O'Brien, J.T. and Levy, R., "Age associated memory impairment", British Medical Jornal, Vol 304, 4 Jan 1992, pp5-6.

48. ВВС, op cit, pp20 and 22.

49. Cited in: Dean, W. and Morgenthaler, J., Smart Drugs and Nutrients, Santa Cruz, Calif., B&J Publications, 1990, p15.

50. MIMS Middle East, Dec 1990, p67.

51. Anon., "Piracetam leads UCB's pharma sales", Scrip, No 1650, 11 Sep 1991, p14.

52. Anon., "Piracetam approved in the UK", Scrip, No 1797, 23 Feb 1993, p21.

53. Anon., "Ondansetron in psychiatry - cautious optimism", Scrip, No 1626, 19 Jun 1991, pp24-5.

54. ВВС, op cit, p22.

55. Anon., "Nooiropics: steroids for stockbrokers?", Scrip, No 1626, 19 Jun 1991, p26.

56. ВВС, op cit, p9.

57. Ibid, pp24-5.

58. Anon.,"FDA cracks down on 'smart drugs'", Scrip, No 1713, 29 Apr 1992, p16.

59. Anon., "Smart Drugs", Which? Way to Health, Feb 1993, pp22-5.

ЭНДРЮ ЧЕТЛИ. ПРОБЛЕМНЫЕ ЛЕКАРСТВА ЭНДРЮ ЧЕТЛИ. ПРОБЛЕМНЫЕ ЛЕКАРСТВА

Содержание:: ANTIBIOTIC.ru

Дата добавления: 2015-07-17